CN1165290C - New medicine release system-liposolubility medicinal preparation - Google Patents
New medicine release system-liposolubility medicinal preparation Download PDFInfo
- Publication number
- CN1165290C CN1165290C CNB011113383A CN01111338A CN1165290C CN 1165290 C CN1165290 C CN 1165290C CN B011113383 A CNB011113383 A CN B011113383A CN 01111338 A CN01111338 A CN 01111338A CN 1165290 C CN1165290 C CN 1165290C
- Authority
- CN
- China
- Prior art keywords
- compositions
- fat
- oil
- tocotrienol
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a new type medicinal composition of a liposoluble medicine that can be readily emulsified with itself in an aqueous medium by slight agitation. The objective medicinal composition comprises a suitable oil, for example, palm olein and/or soybean oil, a proper surfactant, for example, caprylocaproyl macrogol glyceride and polyoxyethylene sorbitan monooleate, and a lipo-soluble medicine. As an example of the liposoluble medicine, tocotrienol, tocopherol, vitamins A, D, K and &beta -caroten are cited.
Description
The present invention relates to a kind of novel formulation of fat-soluble medicine (tocotrienols, tocopherols, vitamin A, D, K and beta-carotene), it can be in gentle agitation in the presence of the water-bearing media and self emulsifying.Particularly, the present invention relates to the preparation of the fat-soluble medicine new dosage form of soft capsule form, it can form emulsion immediately when content is released out and mixes with our gastro-intestinal Fluid.Because known emulsion can promote the absorption of fat-soluble medicine, therefore, this dosage form can make the absorption of medicine better more stable.Successful part of the present invention is: it carries out self emulsifying at gastrointestinal tract ability contains the suitable mixture of suitable oil and the surfactant system composition that suits with it.
Absorption approach such as the absorption approach of the fat-soluble medicine of tocotrienols and tocopherols and other nonpolar lipoids such as triglyceride and cholesterol identical (Kayden and Traber, 1993, lipoid research magazine, 34:343-358).Liver produces bile with the emulsifying of tocopherols medicine, and is mixed together to micelle with other fat-soluble compound and is beneficial to absorption.Dietary fat can promote lipase and biliary generation, so it is essential to the absorption of vitamin E.But if dietary fat is not enough to stimulate the bile secretion of capacity, perhaps bile secretion is influenced by some pathological state, and such as obstruction of biliary tract, the absorption of fat-soluble medicine will become low and unstable so.And known, go on a diet or when taking medicine on an empty stomach the absorption of fat-soluble medicine also will be tending towards low and unstable.
Known Emulsion can improve the absorption of oil-soluble medicine.But because the conventional emulsions volume is bigger, unstable and cause the shelf life short, and mouthfeel is relatively poor, rather than preferred dosage form.Very interested in self-emulsifying drug delivery system (SEDDS) in recent years because this system has a lot of advantages, comprise and can improve bioavailability, can improve the reproduction that blood plasma distributes, and can reduce between the subject and the subject in variability.SEDDS can mix oil under anhydrous condition and make with one or more suitable non-ionic surface active agents.Having enough deliquescent medicine in this oil/surfactant blend can be mixed in this system.In case dilution or in vivo after the administration, under slight the stirring, they can automatically form good oil-in-water emulsion.
Nearest discovers in Mus, δ-, γ-and the bioavailability of alpha-tocotrienol in palm olein and Oleum Glycines mixture be about 2.7,2.8,1.9 times and 2.2,2.1,1.6 times of its bioavailability in the medium chain triglyceride mixture respectively.This may be the long-chain fatty acid owing to palm olein and Oleum Glycines, and its promotes that tocotrienols is absorbed into lymph fluid.A large amount of research (Sieber etc., 1974, Xenobotica 4,265-284 and Palin etc., 1984, pharmacopathology magazine 36,641-643) show long-chain fatty acid (＞C14) (those in palm olein and Oleum Glycines) can improve absorption by lymphoid oil-soluble medicine.
In the light of recent researches, found a kind of new preparation, it carries out suitable mixing with palm olein or Oleum Glycines with the surfactant mixture of a kind of suitable Labrasol (hot hexanoyl polyethyleneglycol glyceride) and Tween80 and obtains.Labrasol to the ratio of Tween80 between 9: 1 to 7: 3.Under slight the stirring (such as the motion of stomach/small intestinal), top system can easily carry out self emulsifying in water.Therefore, this preparation does not need to prepare to become the conventional emulsions of and mouthfeel difference big as volume.And in a kind of soft gel capsule of this mixture can being packed into.Capsule wall dissolving, disintegrate and discharge content under one's belt, this content will form a kind of Emulsion easily.Emulsion can increase the surface area of absorption, therefore can increase the absorption that resembles fat-soluble medicines such as tocotrienols.Also show simultaneously, when mixing the fat-soluble medicine that comprises tocotrienols, tocopherols, vitamin A, vitamin D, vitamin K and beta-carotene etc., comprising can change places with the water capacity with the self-emulsifying drug delivery systems of blended palm olein of surfactant mixture or Oleum Glycines carries out self emulsifying.In addition, when estimating with 12 healthy volunteers, this novel formulation can with δ-, γ-and the absorption of the normal commonly used soft capsule preparation of alpha-tocotrienol improve about 2 to 3 times.Show also simultaneously that for the absorption that improves medicine, surfactant also is very important with the ratio of oil and medicinal mixture.For example, during being in equal proportions of surfactant and medicine and oil mixture, its absorption is relatively poor, and when 1 part of surfactant during to 5 parts of medicines and oil mixture, not only produces autoemulsification preferably, but also at random improve the absorption of medicine.
In a word, this research has been carried out these three kinds important preparation variablees optimizing as much as possible, obtains a kind of good product therefrom, and its bioavailability/absorption is improved, just:
(i) palm olein and Oleum Glycines are used as the carrier that resembles medicines such as tocotrienols, this helps to improve absorption;
(ii) the conjugate with suitable Labrasol and Tween80 adds in medicine/oil mixture, promoting autoemulsification, and therefore helps further to improve the absorption of tocotrienols; With
(iii) with surfactant (Labrasol and Tween80) and combining that oil/medicinal mixture suits, to optimize the absorption of medicine.
Correspondingly, the purpose of this invention is to provide a kind of novel formulation that is used for fat-soluble medicine, it can carry out self emulsifying in water-bearing media under stirring slightly.
This purpose of the present invention is to be used for oral pharmaceutical formulation and to reach by providing a kind of, and this preparation comprises:
(i) a kind of fat-soluble medicine;
(ii) a kind of suitable oil; With
(iii) a kind of suitable surfactant system; The gained preparation can carry out self emulsifying in water-bearing media under slight the stirring.
According to the present invention, a kind of novel formulation of tocotrienols is provided, wherein tocotrienols mixes a kind of palm olein-surfactant system, and forms a kind of self-emulsifying drug delivery systems.This preparation is made soft gel capsule, and under one's belt, content discharges, cause the formation of Emulsion, therefore improve absorption.
Compare with conventional formulation, the preparation of tocotrienols of the present invention has the bioavailability of raising.
Tocotrienols is as Tocomin
50%, comprise minimum 50.0% plant tocotrienols/tocopherols complex, it can be obtained by Carotech (Ipoh, Malaysia) on market.
In the first of this research,, three kinds of different oily carriers are compared at of the influence of different oil to tocotrienols.The oily carrier of being studied is as follows:
(i) palm olein (46.5% Palmic acid, 37.1% oleic acid and 9.9% linoleic triglyceride);
(ii) Oleum Glycines (the linoleic glyceride of 50-57%; The 5-10% linoleic acid, 17-26% oleic acid; 9-13% Palmic acid and 3-6% stearic acid); With
(iii) tricaprylin (satisfied fatty acid sad and triglyceride capric acid is no less than 95%).
Then with 10%Tocomin
50% is dissolved in these three kinds of oily carriers, and gives 9 Mus with identical dosage (10mg) in 3 stages, and these 3 stages are 3 kinds of order crossing research.These 9 Mus are randomized into 3 groups, and 3 every group, and give these preparations according to following table.
| Group | Phase | ||
| I | II | III | |
| 1 2 3 | Palm olein tricaprylin Oleum Glycines | Oleum Glycines palm olein tricaprylin | Tricaprylin Oleum Glycines palm olein |
Before absorption experiment begins and the beginning after respectively with these animal fasting 12 hours.But in whole experiment, allow them freely to drink water.Subsequently these animals are put into the control cage, and heparinization is inserted in vitro from the about 0.5ml of its tail vein blood with blood specimen in 1,2,3,4,6,8 and 12 hour after administration respectively.Then under 12800G with centrifugal 10 minutes of blood specimen, and the five equilibrium blood plasma of gained 0.2-0.3ml is transferred in the new Eppendorf test tube.Immediately that all plasma specimens is freezing under-20 ℃, up to analyzing.
Use reported method in 1999 such as Yap (" chromatography magazine B ", 735:279-283), slightly modified, by high efficiency liquid chromatography (HPLC) measure blood plasma α-, δ-and γ-tocotrienol.
Accompanying drawing 1a, 1b and 1c be α-, δ-and the mean plasma concentration of γ-tocotrienol and curve chart of time, they are by Tocomin
50% is obtained in three kinds of oleaginous bases, and these three kinds of oleaginous bases are palm olein, Oleum Glycines and medium chain triglyceride.Can significantly find out Tocomin from figure and result
50% in palm olein gained α-, δ-and the absorption maximum of γ-tocotrienol, secondly be Tocomin
50% in Oleum Glycines, Tocomin
50% absorption minimum in tricaprylin.The difference of the bioavailability of three kinds of homologues of the tocotrienol of different oiliness carriers has statistical significance.
From to number conversion AUC
0-∝90% confidence interval of the ratio of value can be found out significantly, compares Tocomin with tricaprylin
50% absorption height in palm olein and Oleum Glycines, for α-, δ-and γ-tocotrienol, it approximately is Tocomin
50% in tricaprylin 2.7,2.8,1.9 and 2.2,2.1,1.6 times.Therefore can clearly illustrate that palm olein and Oleum Glycines can improve their absorption significantly as a kind of carrier of tocotrienols in the research in this section.
In second portion research, the surfactant system of different proportion can form a kind of self-emulsifying drug delivery system (SEDDS).The purpose of this part research is that tocotrienol is mixed a kind of suitable surfactant system, and this system can make this preparation (oil base tocotrienol) easily carry out a kind of Emulsion of self emulsifying/form under slight stirring.This slight stirring is such as the motion that is stomach/intestinal.Dissimilar SEDDS can comprise following system:
(i) Tween 85-medium chain triglyceride (MCT)
(ii) Tween 80-Span 80-palm olein
(iii) Labrasol-Tween 80-palm olein/Oleum Glycines
SEDDS can mix oil and prepare with non-ionic surface active agent, fat base and fat-soluble medicine under anhydrous condition, in this case, and side's property oil solutions such as tocotrienol formation.In case dilute with water or administration in vivo, they can form good oil in water emulsion.Find that Labrasol-Tween 80-palm olein/Oleum Glycines is best system, reason is as follows:
(i) compare with other two kinds of systems, it can mix the more tocotrienol of volume, and does not offset emulsification;
The absorption of tocotrienol of (ii) finding medium chain triglyceride from the research of first is less than palm olein.Therefore do not need to use Tween 85-medium chain triglyceride; With
(iii) between Tween 80-Span 80-palm olein and Labrasol-Tween 80-palm olein/Oleum Glycines, the latter has emulsification rate and stability reliably.
According to the present invention, last main preparation is as follows:
| Component | Weight in each capsule (mg) |
| Tocomin 50％ | 148.66 |
| Palm olein/Oleum Glycines | 351.34 |
| Labrasol | 87.00 |
| Tween 80 | 13.00 |
| Gross weight | 600.00 |
The scope of oil and surfactant ratio is end formulation ± 10%.Oil remains on 5 to 1 with the ratio of surfactant, to avoid taking place solubilization.On a kind of critical micelle concentration of surfactant system, the micelle complexation reaction of tocotrienol can take place.Knownly ignore the absorption that is mixed into micellar medicine.Because the medicine in the micellar phase is nonabsorbable, thus concentration medicine less than its apparent concentration, and find absorbance reduce (Gibaldi and Feldman, 1970, " materia medica magazine ", 59:579-589).
With Tocomin
50% with the palm olein mix homogeneously, and with Labrasol and Tween 80 mix homogeneously.Then surfactant and this oil mixture are mixed.Before the soft gel capsule of packing into, with the final mixture mix homogeneously.
In third part, carry out the research of bioavailability in a kind of body, it is when the dosage level of tocotrienol is 200mg, with the bioavailability of tocotrienol and the comparing of common dosage forms of novel formulation.Novel formulation comprises tocotrienol, palm olein, Labrasol and Tween80, and its ratio is identical with top main formula.Normal common dosage forms comprises tocotrienol and Oleum Glycines.These two kinds of products are the form of soft gel capsule.
At signature informed consent postscript, 12 volunteers of NAM add 2 stages of standard, in 2 order crossing research.These volunteers are divided into 2 groups at random, every group 6 people, and carry out administration shown in the according to the form below:
| Group | Phase | |
| I | II | |
| 1 2 | Common dosage forms novel formulation (X) | Novel formulation (X) common dosage forms |
In first experiment periods, give 4 common dosage forms of each volunteer (Y) capsule in the group 1, give 4 novel formulation of each volunteer (X) capsule in the group 2, they contain the tocotrienol of equal dose.After the rest period in a week, each volunteer accepts another kind of product again.After fasting a whole night, (10:00) takes these products with 240ml water in the morning.Do not give any F﹠B in back 4 hours taking medicine, can drink pure water arbitrarily.Supplied with lunch and supper in after taking medicine 4 hours and 10 hours.Lunch and supper contain Carnis Gallus domesticus and rice.0 (before taking medicine) after taking medicine, 1,2,3,4,5,6,7,8,10,12,14,18,24 hour by a trocar that places forearm, go into the 5ml blood sample collection in the vacuum test tube (to contain heparin sodium as anticoagulant).Under 2000G,, and blood plasma moved in the separation of glasses test tube, keep freezing up to analyzing with centrifugal 15 minutes of blood specimen.
The scheme of this research obtains materia medica school, and the USM-general hospital Penang committee of research bioavailability unites approval.Before experiment, give the volunteer with the data of this medicine and the character of this research.
Use the reversed phase high efficiency liquid chromatography analysed for plasma α of report such as Yap-, δ-and the level of γ-tocotrienol (1999, " chromatography magazine B ", 735:279-283).
Accompanying drawing 2a, 2b and 2c be common dosage forms and novel formulation α-, δ-and the mean plasma concentration of γ-tocotrienol and curve chart of time.Can be clear that from figure for the homologue of these three kinds of tocotrienol, the curve of novel formulation is apparently higher than the curve of common dosage forms.And the absorption of the absorptance common dosage forms of novel formulation begins early.In addition, in using the individuality of common dosage forms, some do not detect δ-and γ-tocotrienol (γ-tocotrienol of δ-tocotrienol of 3 subjects and 1 subject).On the contrary, all detect this two kinds of tocotrienol in all subjects that use novel formulation, this absorption that shows this preparation is better.
To number conversion AUC
0-∝Difference between the value has statistical significance (P＜0.01), all homologues of these two kinds of preparations to number conversion C
MaxValue also has statistical significance (P＜0.01).
In addition, to number conversion AUC
0-∝90% confidence interval of the ratio of value can estimate, respectively for δ-, γ-and alpha-tocotrienol, the average degree of novel formulation (X) is 2.6,2.9 and 3.0 times of common dosage forms (Y).At parameter T
MaxDown, the numerical value of novel formulation is less than common dosage forms, and this shows that the former has faster and begins/drug absorption speed.T between these two kinds of preparations
MaxThe difference of value has statistical significance (P＜0.05).
Can draw according to the result who studies above: novel formulation is compared with common dosage forms, the degree of absorption of tocotrienol can be improved significantly.And the beginning or the infiltration rate of novel formulation are very fast.
Here described the preferred embodiments of the present invention, also can carry out different changes and modification the present invention.Therefore should be realized that the present invention is not limited in the detailed description, those of ordinary skill in the art, the change that little detailed description like this is done is conspicuous.
Claims (7)
1. a self emulsifying medicament provides the compositions of the oral form with fat-soluble medicament, and described compositions comprises:
A kind of fat-soluble medicament, it is selected from tocotrienol, tocopherol, vitamin A, D or K or beta-carotene;
A kind of oil, it is selected from Petiolus Trachycarpi oil or soybean oil;
A kind of surfactant system, it comprises first component of being made up of hot hexanoyl polyethyleneglycol glyceride, by second component that polyoxyethylene 20 Arlacel-80s are formed, the weight ratio of wherein said first component and second component between 9: 1 to 7: 3,
Wherein said compositions strengthens the absorbability of described fat-soluble medicament.
2. compositions as claimed in claim 1, wherein fat-soluble medicament is a tocotrienol.
3. compositions as claimed in claim 1, wherein fat-soluble medicament and oil are about 5: 1 with the weight ratio of surfactant system.
4. compositions as claimed in claim 1, wherein said component is taken with the form of soft gel capsule.
5. compositions as claimed in claim 1, wherein said component is self emulsifying in the presence of aqueous solution.
6. compositions as claimed in claim 5, wherein said self emulsifying occurs under the existence of the intestines and stomach liquid.
7. the method for compositions for preparing claim 1, it is characterized in that, fat-soluble medicament is mixed with oil until evenly producing a kind of oily mixture, first kind of composition of surfactant system mixed with second kind of composition and produce surfactant system, oily mixture is mixed with surfactant mixture until the mixture that evenly produces compositions, and with composition mixture a kind of soft gel capsule of packing into.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI20002572 MY120392A (en) | 2000-06-08 | 2000-06-08 | A novel drug delivery system : formulation for fat-soluble drugs |
| MYPI20002572 | 2000-06-08 | ||
| US09/612,434 | 2000-07-07 | ||
| US09/612,434 US6596306B1 (en) | 2000-07-07 | 2000-07-07 | Drug delivery system:formulation for fat-soluble drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1339297A CN1339297A (en) | 2002-03-13 |
| CN1165290C true CN1165290C (en) | 2004-09-08 |
Family
ID=26641506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB011113383A Expired - Lifetime CN1165290C (en) | 2000-06-08 | 2001-01-23 | New medicine release system-liposolubility medicinal preparation |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1165290C (en) |
| HK (1) | HK1043944A1 (en) |
| SG (1) | SG97918A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106667920A (en) * | 2016-12-29 | 2017-05-17 | 陕西科技大学 | Vitamin A nanoparticle and preparation method thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100361656C (en) * | 2004-08-27 | 2008-01-16 | 石药集团中奇制药技术（石家庄）有限公司 | Butylbenzene phthalein self emulsifying releasing medicine system, preparation method and application |
| CN1660064B (en) * | 2004-12-28 | 2010-09-29 | 中山大学 | Nage lieqin self-emulsifying system for releasing medicine |
| MY182652A (en) * | 2014-11-25 | 2021-01-27 | Kl Kepong Oleomas Sdn Bhd | Formulation for effective tocotrienol delivery |
-
2000
- 2000-07-26 SG SG200004450A patent/SG97918A1/en unknown
-
2001
- 2001-01-23 CN CNB011113383A patent/CN1165290C/en not_active Expired - Lifetime
-
2002
- 2002-07-15 HK HK02105207A patent/HK1043944A1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106667920A (en) * | 2016-12-29 | 2017-05-17 | 陕西科技大学 | Vitamin A nanoparticle and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| SG97918A1 (en) | 2003-08-20 |
| CN1339297A (en) | 2002-03-13 |
| HK1043944A1 (en) | 2002-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101926757B (en) | Liquid composition of indissolvable medicines and preparation method thereof | |
| US5614491A (en) | Liquid preparations containing cyclosporin and process for preparing same | |
| US6596306B1 (en) | Drug delivery system:formulation for fat-soluble drugs | |
| US20070009559A1 (en) | Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same | |
| KR101716878B1 (en) | Pharmaceutical Capsule Composite Formulation of Dutasteride and Tadalafill Comprising Glycerol Fatty Acid Ester Derivative or Propylene Glycol Fatty Acid Ester Derivative And Method For Preparation thereof | |
| CN1197551C (en) | Dispersion formulations contg. lipase inhibitors | |
| US20150283242A1 (en) | Effective pharmaceutical carrier for poorly bioavailable drugs | |
| NZ209526A (en) | Clear micellised aqueous solutions of fat soluble essential nutrients | |
| JP2004189753A (en) | Emulsion preconcentrate containing cyclosporin or macrolide | |
| CN1261796A (en) | Self-emulsifying formulation for lipophilic compounds | |
| US20030180350A1 (en) | Combination compositions | |
| CN1165290C (en) | New medicine release system-liposolubility medicinal preparation | |
| EP1498143A1 (en) | Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids | |
| CN1114588A (en) | Formulations for orally administered pharmaceutical agents | |
| AU771439B2 (en) | A novel drug delivery system : formulation for fat-soluble drugs | |
| KR100426346B1 (en) | Pharmaceutical compositions for Hypercholesterolemia treatment using of Self Emulsifying drug delivery system | |
| WO2000009085A2 (en) | Oral formulation containing cyclosporin | |
| AU2015354848B2 (en) | Formulation for effective tocotrienol delivery | |
| RU2216342C2 (en) | Cyclosporin solution | |
| JP2973077B2 (en) | Vitamin E preparation composition | |
| KR100524700B1 (en) | Pharmaceutical compositions for Hyperlipidemia treatment using of Self Emulsifying drug delivery system | |
| AU635248B2 (en) | Use of mixed micelles | |
| US20050220866A1 (en) | Novel capsule formulations of etoposide for oral use | |
| KR20050030282A (en) | Formulation and manufacturing process solubilized simvastatin soft capsules | |
| CZ202125A3 (en) | Microemulsion preconcentrate containing cladribine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1043944 Country of ref document: HK |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20040908 |